Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Japanese GPP and EP
NCT03022045Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in generalized pustular psoriasis (GPP), erythrodermic psoriasis (EP), sponsored by AbbVie Inc.. Started Jan 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
generalized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on NCT03022045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022045.